Next-Generation Sequencing (NGS) Assessment of Homologous Recombination Deficiency (HRD): Expanding NGS Data to View Events Associated with Genomic Instability

NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are currently on-market targeted by tumor genotype, and research is ongoing to identify other genomic alterations that can be used for stratification and drug development. This webinar describes an approach to genomic discovery that processes NGS data via NxClinical software from Bionano Genomics to assess solid tumors for genomic instability states associated with HRD.

 

Learning Objectives